In vitro characterization of [ 18F]-florbetaben, an Aβ imaging radiotracer

Nuclear Medicine and Biology

Volumn 39, Issue 7, 2012, Pages 1042-1048

  Fodero Tavoletti, Michelle T ^a,b   Brockschnieder, Damian ^c   Villemagne, Victor L ^d,e   Martin, Lucas ^c   Connor, Andrea R ^a,b   Thiele, Andrea ^c   Berndt, Mathias ^c   McLean, Catriona A ^f   Krause, Sabine ^c   Rowe, Christopher C ^d   Masters, Colin L ^e   Dinkelborg, Ludger ^c   Dyrks, Thomas ^c   Cappai, Roberto ^a,b  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c BAYER PHARMA AG   (Germany)

^d AUSTIN HEALTH   (Australia)

^e FLOREY INSTITUTE OF NEUROSCIENCE AND MENTAL HEALTH   (Australia)

^f ALFRED HOSPITAL   (Australia)

Author keywords

A ; Alzheimer's disease; Dementia; Imaging; PET

Indexed keywords

ALPHA SYNUCLEIN; AMYLOID BETA PROTEIN; FLORBETABEN; TAU PROTEIN; 4 (N METHYLAMINO) 4' (2 (2 (2 FLUOROETHOXY)ETHOXY)ETHOXY)STILBENE; 4-(N-METHYLAMINO)-4'-(2-(2-(2-FLUOROETHOXY)ETHOXY)ETHOXY)STILBENE; ANILINE DERIVATIVE; DIAGNOSTIC AGENT; STILBENE DERIVATIVE; TRACER;

ADULT; AGED; ALZHEIMER DISEASE; AMYLOID PLAQUE; ARTICLE; AUTORADIOGRAPHY; CLINICAL ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DIFFUSE LEWY BODY DISEASE; DRUG PROTEIN BINDING; DRUG SELECTIVITY; FEMALE; FLUORESCENCE MICROSCOPY; FRONTOTEMPORAL DEMENTIA; HUMAN; HUMAN TISSUE; IN VITRO STUDY; MALE; MOLECULAR IMAGING; POSITRON EMISSION TOMOGRAPHY; CHEMISTRY; ENZYME SPECIFICITY; METABOLISM; MIDDLE AGED; PATHOLOGY;

AGED; AGED, 80 AND OVER; ALPHA-SYNUCLEIN; ANILINE COMPOUNDS; FEMALE; HUMANS; MALE; MIDDLE AGED; MOLECULAR IMAGING; PLAQUE, AMYLOID; RADIOACTIVE TRACERS; STILBENES; SUBSTRATE SPECIFICITY; TAU PROTEINS;

EID: 84866025788     PISSN: 09698051     EISSN: 18729614     Source Type: Journal    
DOI: 10.1016/j.nucmedbio.2012.03.001     Document Type: Article

References (34)

1. Masters C.L., Cappai R., Barnham K.J., Villemagne V.L. Molecular mechanisms for Alzheimer's disease: implications for neuroimaging and therapeutics. J Neurochem 2006, 97:1700-1725.
2. Haass C., Selkoe D.J. Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid beta-peptide. Nat Rev Mol Cell Biol 2007, 8:101-112.
3. Klunk W.E., Engler H., Nordberg A., Wang Y., Blomqvist G., Holt D.P., et al. Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B. Ann Neurol 2004, 55:306-319.
4. Ikonomovic M.D., Klunk W.E., Abrahamson E.E., Mathis C.A., Price J.C., Tsopelas N.D., et al. Post-mortem correlates of in vivo PiB-PET amyloid imaging in a typical case of Alzheimer's disease. Brain 2008, 131:1630-1645.
5. Maeda J., Ji B., Irie T., Tomiyama T., Maruyama M., Okauchi T., et al. Longitudinal, quantitative assessment of amyloid, neuroinflammation, and anti-amyloid treatment in a living mouse model of Alzheimer's disease enabled by positron emission tomography. J Neurosci 2007, 27:10957-10968.
6. Rowe C.C., Ng S., Ackermann U., Gong S.J., Pike K., Savage G., et al. Imaging beta-amyloid burden in aging and dementia. Neurology 2007, 68:1718-1725.
7. Kemppainen N.M., Aalto S., Wilson I.A., Nagren K., Helin S., Bruck A., et al. Voxel-based analysis of PET amyloid ligand [11C]PIB uptake in Alzheimer disease. Neurology 2006.
8. Clark C.M., Schneider J.A., Bedell B.J., Beach T.G., Bilker W.B., Mintun M.A., et al. Use of florbetapir-PET for imaging beta-amyloid pathology. JAMA 2011, 305:275-283.
9. Agdeppa E.D., Kepe V., Liu J., Flores-Torres S., Satyamurthy N., Petric A., et al. Binding characteristics of radiofluorinated 6-dialkylamino-2-naphthylethylidene derivatives as positron emission tomography imaging probes for beta-amyloid plaques in Alzheimer's disease. J Neurosci 2001, 21:RC189.
10. Rowe C.C., Ackerman U., Browne W., Mulligan R., Pike K.L., O'Keefe G., et al. Imaging of amyloid beta in Alzheimer's disease with 18F-BAY94-9172, a novel PET tracer: proof of mechanism. Lancet Neurol 2008, 7:129-135.
11. Wong D.F., Rosenberg P.B., Zhou Y., Kumar A., Raymont V., Ravert H.T., et al. In vivo imaging of amyloid deposition in Alzheimer disease using the radioligand 18F-AV-45 (flobetapir F 18). J Nucl Med 2010, 51:913-920.
12. Vandenberghe R., Van Laere K., Ivanoiu A., Salmon E., Bastin C., Triau E., et al. 18F-flutemetamol amyloid imaging in Alzheimer disease and mild cognitive impairment: a phase 2 trial. Ann Neurol 2010, 68:319-329.
13. Barthel H., Gertz H.J., Dresel S., Peters O., Bartenstein P., Buerger K., et al. Cerebral amyloid-beta PET with florbetaben (18F) in patients with Alzheimer's disease and healthy controls: a multicentre phase 2 diagnostic study. Lancet Neurol 2011, 10:424-435.
14. Shoghi-Jadid K., Small G.W., Agdeppa E.D., Kepe V., Ercoli L.M., Siddarth P., et al. Localization of neurofibrillary tangles and beta-amyloid plaques in the brains of living patients with Alzheimer disease. Am J Geriatr Psychiatry 2002, 10:24-35.
15. Villemagne V.L., Ong K., Mulligan R.S., Holl G., Pejoska S., Jones G., et al. Amyloid imaging with (18)F-florbetaben in Alzheimer disease and other dementias. J Nucl Med 2011, 52:1210-1217.
16. 18F]florbetaben (BAY 94-9172) in human subjects: a substudy within a proof of mechanism clinical trial. J Radioanalytic Nucl Chem 2010, 284:557-562.
17. Zhang W., Oya S., Kung M.P., Hou C., Maier D.L., Kung H.F. F-18 polyethyleneglycol stilbenes as PET imaging agents targeting Abeta aggregates in the brain. Nucl Med Biol 2005, 32:799-809.
18. Clinical and neuropathological criteria for frontotemporal dementia. The Lund and Manchester Groups. J Neurol Neurosurg Psychiatry 1994, 57:416-418.
19. McKeith I.G., Galasko D., Kosaka K., Perry E.K., Dickson D.W., Hansen L.A., et al. Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the consortium on DLB international workshop. Neurology 1996, 47:1113-1124.
20. Weisman D., McKeith I. Dementia with Lewy bodies. Semin Neurol 2007, 27:42-47.
21. Tammer A.H., Coia G., Cappai R., Fuller S., Masters C.L., Hudson P., et al. Generation of a recombinant Fab antibody reactive with the Alzheimer's disease-related Abeta peptide. Clin Exp Immunol 2002, 129:453-463.
22. Price J.L., Morris J.C. Tangles and plaques in nondemented aging and "preclinical" Alzheimer's disease. Ann Neurol 1999, 45:358-368.
23. Villemagne V.L., Pike K.E., Darby D., Maruff P., Savage G., Ng S., et al. Abeta deposits in older non-demented individuals with cognitive decline are indicative of preclinical Alzheimer's disease. Neuropsychologia 2008, 46:1688-1697.
24. Rowe C.C., Ellis K.A., Rimajova M., Bourgeat P., Pike K.E., Jones G., et al. Amyloid imaging results from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging. Neurobiol Aging 2010.
25. Morris J.C., Roe C.M., Grant E.A., Head D., Storandt M., Goate A.M., et al. Pittsburgh compound B imaging and prediction of progression from cognitive normality to symptomatic Alzheimer disease. Arch Neurol 2009, 66:1469-1475.
26. Villemagne V.L., Pike K.E., Chetelat G., Ellis K.A., Mulligan R.S., Bourgeat P., et al. Longitudinal assessment of Abeta and cognition in aging and Alzheimer disease. Ann Neurol 2011, 69:181-192.
27. Rinne J.O., Brooks D.J., Rossor M.N., Fox N.C., Bullock R., Klunk W.E., et al. 11C-PiB PET assessment of change in fibrillar amyloid-beta load in patients with Alzheimer's disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study. Lancet Neurol 2010, 9:363-372.
28. Nordberg A. PET imaging of amyloid in Alzheimer's disease. Lancet Neurol 2004, 3:519-527.
29. Thal D.R., Rub U., Orantes M., Braak H. Phases of A beta-deposition in the human brain and its relevance for the development of AD. Neurology 2002, 58:1791-1800.
30. Braak H., Braak E. Frequency of stages of Alzheimer-related lesions in different age categories. Neurobiol Aging 1997, 18:351-357.
31. Thal DR, Capetillo-Zarate E, Del Tredici K, and Braak H. The development of amyloid beta protein deposits in the aged brain. Sci Aging Knowledge Environ 2006;2006:re1.
32. Alafuzoff I., Pikkarainen M., Arzberger T., Thal D.R., Al-Sarraj S., Bell J., et al. Inter-laboratory comparison of neuropathological assessments of beta-amyloid protein: a study of the BrainNet Europe consortium. Acta Neuropathol 2008, 115:533-546.
33. Trojanowski J.Q. Emerging Alzheimer's disease therapies: focusing on the future. Neurobiol Aging 2002, 23:985-990.
34. LeVine H. Quantification of beta-sheet amyloid fibril structures with thioflavin T. Methods Enzymol 1999, 309:274-284.